Brief: Hofseth Biocare: Aecorbio Secures Further $1.5 Mln At $30 Mln Valuation
17/09/2025 08:00
Sept 17 (Reuters) - Hofseth Biocare ASA HBC.OL: HOFSETH BIOCARE ASA: AECORBIO SECURES A FURTHER $1.5M AT A $30M VALUATION FOR ONGOING FT-002A PEPTIDE DEVELOPMENT IN PROSTATE CANCER Source text: ID:nGNE1XNnqt Further company coverage: HBC.OL (Gdansk Newsroom) ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on Hofseth Biocare ASA
See all newsBrief: Hofseth BioCare Board Member Buys 2.5 Mln Shares in Company
Brief: Hofseth Biocare Appoints Leif Arne Giske As CFO
Hofseth BioCare Q2 operating revenue slips on lower raw material volumes
Brief: Hofseth Biocare Q2 Revenue NOK 65.7 Million
Brief: Research Corporation Buys 14.3 Mln Shares In Hofseth Biocare